Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Indonesia ETF (EIDO) vs Humana Inc (HUM) Price & Performance

iShares MSCI Indonesia ETFTrade
Humana IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Indonesia ETF vs Humana Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 113.6× iShares MSCI Indonesia ETF's market cap, and Humana Inc pays a 0.91% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Humana Inc for 51 Days on average.

EIDOHUM
Market Cap
$409.22M$46.49B
Volume
879,5272,567,704
52-Week High
$19.22$409.85
52-Week Low
$10.80$163.67
Typical Hold Time
76 Days51 Days
Sector
—Health
Enterprise Value
—$53.84B
Dividend Yield
—0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Indonesia ETF

EIDO (iShares MSCI Indonesia ETF) trades at $11.89, up 0.25% with bearish technical signals from moving averages. The ETF faces headwinds from foreign capital outflows in Asian equities and limited upside from its heavy financials weighting. Recent news highlights Indonesia's underperformance despite commodity gains, with trading volume declining 21% below average.

Outlook remains cautious given technical downtrend and sector concentration risks. The ETF's bargain 8.7x P/E offers value but weak price action and low EPS growth constrain momentum. Key risks include regional capital rotation and dependence on financial sector performance.

Humana Inc

Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.

The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EIDO
92% Buy8% Sell
Avg holding period · 76 Days
HUM
93% Buy7% Sell
Avg holding period · 51 Days

Top news

Latest headlines on both assets

About iShares MSCI Indonesia ETF

The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.

Read more on EIDO →

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →